Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy
- PMID: 16624603
- DOI: 10.1016/j.ghir.2006.03.004
Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy
Abstract
Overweight adults with impaired glucose tolerance have a 5-10% risk of developing diabetes per year, and insulin resistance is an important cause of progression to diabetes in these individuals. Weight loss has been shown to improve insulin sensitivity and prevent or delay progression to diabetes. According to recent studies, the improvement in insulin sensitivity that occurs with weight loss is closely linked to the reduction of visceral adipose tissue (VAT), the collection of intra-abdominal adipose depots that includes omental and intrahepatic fat. After controlling for BMI, whole body fat, and subcutaneous fat, only VAT is an independent predictor of endogenous insulin sensitivity and glucose tolerance before or after weight loss. This, in turn, suggests that reducing VAT is crucial to improving insulin sensitivity and preventing diabetes in high-risk individuals. Recombinant human growth hormone (GH) is a lipolytic drug that reduces total body, abdominal, and visceral fat in growth hormone-deficient (GHD) adults. Several studies have reported substantial reductions in VAT following GH treatment in this population. Like GHD adults, abdominally obese individuals have increased VAT, insulin resistance, and growth hormone levels that are below normal during continuous 24-h monitoring. These similarities have prompted a number of recent investigations in abdominally obese adults that reported significant reductions in truncal and visceral fat and an improvement in insulin sensitivity following prolonged GH administration. However, other studies have shown that insulin resistance and glucose concentrations transiently worsen during the first few weeks of GH treatment and that these deleterious effects can persist even after VAT reduction has occurred. Prior studies involving GH treatment were generally limited to adults who were normoglycemic at baseline. Less is known about the effects of GH in adults with impaired glucose tolerance or diabetes. The effects of GH used in conjunction with insulin sensitizers on glycemic control and VAT in patients with impaired glucose tolerance will be reviewed.
Similar articles
-
Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.Growth Horm IGF Res. 2006 Jul;16 Suppl A:S55-61. doi: 10.1016/j.ghir.2006.03.001. Epub 2006 Apr 18. Growth Horm IGF Res. 2006. PMID: 16624605 Review.
-
Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.Diabetes Obes Metab. 2007 Jan;9(1):11-22. doi: 10.1111/j.1463-1326.2006.00591.x. Diabetes Obes Metab. 2007. PMID: 17199714 Review.
-
Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.Clin Endocrinol (Oxf). 2006 Apr;64(4):444-9. doi: 10.1111/j.1365-2265.2006.02490.x. Clin Endocrinol (Oxf). 2006. PMID: 16584518 Clinical Trial.
-
[Application of extended hyperinsulinemic euglycemic clamp in the assessment of insulin sensitivity in obese individuals with glucose intolerance].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Dec;28(6):740-4. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006. PMID: 17260458 Chinese.
-
Growth hormone and the metabolic syndrome.J Endocrinol Invest. 1999;22(5 Suppl):41-6. J Endocrinol Invest. 1999. PMID: 10442570 Review.
Cited by
-
The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity.Metabolites. 2022 Dec 5;12(12):1221. doi: 10.3390/metabo12121221. Metabolites. 2022. PMID: 36557260 Free PMC article.
-
Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study.Nutrients. 2021 Oct 19;13(10):3665. doi: 10.3390/nu13103665. Nutrients. 2021. PMID: 34684666 Free PMC article. Clinical Trial.
-
The effect of chronic intermittent hypobaric hypoxia improving liver damage in metabolic syndrome rats through ferritinophagy.Pflugers Arch. 2023 Nov;475(11):1251-1263. doi: 10.1007/s00424-023-02860-6. Epub 2023 Sep 25. Pflugers Arch. 2023. PMID: 37747537
-
Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome.J Clin Endocrinol Metab. 2008 Jun;93(6):2109-14. doi: 10.1210/jc.2007-2266. Epub 2008 Mar 18. J Clin Endocrinol Metab. 2008. PMID: 18349057 Free PMC article.
-
Impaired endothelial function in pediatric patients with turner syndrome and healthy controls: a case-control study.Int J Pediatr Endocrinol. 2012 Apr 2;2012(1):5. doi: 10.1186/1687-9856-2012-5. Int J Pediatr Endocrinol. 2012. PMID: 22472028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical